MAZE - Maze Therapeutics, Inc.
44.83
-0.470 -1.048%
Share volume: 383,490
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.19%
PREVIOUS CLOSE
CHG
CHG%
$45.30
-0.47
-0.01%
View ratios
| Fiscal Date | 03-31-2025 | 09-30-2025 | |
|---|---|---|---|
| Fiscal Quarter | Q1 2025 | Q3 2025 | |
| Report Date | 05-14-2025 | 11-06-2025 | |
| Total revenue | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | |
| nan% | |||
| Operating expenses | 35.401 M | 32.965 M | |
| Selling general and admin | 7.821 M | 7.775 M | |
| Research and development | 27.580 M | 25.190 M | |
| Total expenses | 35.401 M | 32.965 M | |
| -6.88% | |||
| Operating income | -35.401 M | -32.965 M | |
| Ebit | -35.401 M | -32.965 M | |
| Pretax income | -32.786 M | -30.087 M | |
| -8.23% | |||
| Income tax | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | |
| Net income | -32.786 M | -30.087 M | |
| 8.23% |